Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon

Hepato-Gastroenterology

Volumn 55, Issue 84, 2008, Pages 916-920

  Tursi, Antonio ^a,b,d   Brandimarte, Giovanni ^b   Giorgetti, Gian Marco ^c   Elisei, Walter ^b  

^a Lorenzo Bonomo Hospital   (Italy)

^b Cristo Re Hospital   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

^d NONE   (Italy)

Author keywords

Mesalazine; Probiotics; Recurrence; Symptomatic diverticular disease; Treatment

Indexed keywords

LACTOBACILLUS CASEI EXTRACT; MESALAZINE; PENTACOL;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; COLON DISEASE; CONTROLLED STUDY; DIVERTICULOSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; DIVERTICULITIS, COLONIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LACTOBACILLUS CASEI; LONG-TERM CARE; MALE; MESALAMINE; MIDDLE AGED; PROBIOTICS; PROSPECTIVE STUDIES; RECURRENCE;

EID: 47149108022     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. West AB, Losada M: The pathology of diverticulosis coli. J Clin Gastroenterol 2004; 38:11-16.
2. Tursi A: Acute diverticulitis of the colon - current medical therapeutic management. Exp Opin Pharmacother 2004; 5(1):145-149.
3. Tursi A, Brandimarte G, Daffinà R: Long-term treatment with mesalazine and rifaximin versus rifaximin alone for the patients with recurrent attacks of acute diverticulitis of the colon. Dig Liver Dis 2002; 34(7):510-515.
4. Brandimarte G, Tursi A: Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. Med Sci Monit 2004; 10(5):170-173.
5. Latella G, Pimpo MT, Sottili S et al: Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 2003; 18(1):55-62.
6. Sanders ME: Probiotics. Food Technology 1999; 53:67-77.
7. Gionchetti P, Amadini C, Rizzello F et al: Probiotics - Role in inflammatory bowel disease. Dig Liver Dis 2002; 34:58-62.
8. Isolauri E: Probiotics for infectious diarrhea. Gut 2003; 52(3):436-437.
9. Bazzocchi G, Gionchetti P, Almerigi PF, Amadini C, Campieri M: Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. Digest Liver Dis 2002; 34:48-53.
10. Cremonini F, Di Caro S, Covino M et al: Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side-effects:a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002; 97(11):2744-2749.
11. Frič P, Zavoral M: The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 2003; 15(3):313-315.
12. Tursi A, Brandimarte G, Giorgetti GM, Elisei W: Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon:a prospective, randomised, open-label study. J Clin Gastroenterol 2006; 40(4):312-316.
13. Stollman NH, Raskin JB: Diverticular disease of the colon. J Clin Gastroenterol 1999; 29(3):241-252.
14. Tursi A: Preventive therapy for complicated diverticular disease of the colon: looking for a correct therapeutic approach. Gastroenterology 2004; 127(6):1865-1866.
15. Eliakim R, Rachmilewitz D: Potential mediators in inflammatory bowel disease. Gastroenterology Int 1992; 5:48-56.
16. Grisham MB: Oxidants and free radicals in inflammatory bowel disease. Lancet 1994; 344:859-861.
17. Hanauer SB: Inflammatory bowel disease. N Engl J Med 1996; 334(13):841-848
18. Gonçalves E, Almeida LM, Dinis TC: Antioxidant activity of 5-aminosalicylic acid against peroxidation of phosphatidylcholine liposomes in the presence of alpha-tocopheroha synergistic interaction? Free Rad Res 1998; 29(1):53-66.
19. Floch MH, Bina I: The natural history of diverticulitis: fact and theory. J Clin Gastroenterol 2004: 38:S2-S7.
20. Dugas B, Mercenier A, Lenoir-Wijnkoop I, Arnaud C, Dugas N, Postaire E: Immunity and probiotics. Immunol Today 1999; 20(9):387-390.
21. Bengmark S: Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut 1998; 42(1):2-7.
22. Borruel N, Casellas F, Antolin M et al: Effects of non-pathogenic bacteria on cytokine secretion by human intestinal mucosa. Am J Gastroenterol 2003; 98:865-870.
23. Giaccari S, Tronci S, Falconieri M, Ferrieri A: Long-term treatment with rifaximin and lactobacilli in post-diverticulitic stenoses of the colon. Eur Rev Med Pharmacol Sci 1993; 15(1):29-34.
24. Comparato G, Fanigliulo L, Cavallaro LG et al: Prevention and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. Dig Dis Sci 2007; 52(11):2934-2941
25. Tursi A, Brandimarte G, Giorgetti GM, Elisei W: Continuative versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. Dig Dis Sci 2007; 52(3):671-674.
26. Drago L, De Vecchi E, Valli M, Nicola L, Lombardi A, Gismondo MR: Colonizzazione intestinale di Lactobacillus casei subsp. Casei I-1572 CNCM (L. casei DG) in volontari sani e in topi germ-free. Farmaci & Terapia 2002; XIX:72-76. (In Italian)
27. Venturi A, Gionchetti P, Rizzello F et al: Impact on the composition of the faecal flora by a new probiotic preparation:preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13(8):1103-1108.
28. Tursi A, Brandimarte G, Giorgetti GM, et al: Assess ment and grading of mucosal inflammation in colonic diverticular disease. J Clin Gastroenterol 2008 (Epub ahead of print) PMID 847509
29. Tursi A: New physiopathological and therapeutic approaches to diverticular disease disease of the colon. Exp Opin Pharmacother 2007; 8(3):299-307.